In benign prostatic hyperplasia (BPH), the Ber/Pal combination moderately inhibits key inflammatory targets 5-lipoxygenase (LOX-5) and cyclooxygenase-2 (COX-2), ameliorating BPH pathology (Wang et al., 2021). This evidence concerns the gene PTGS2 and benign prostatic hyperplasia.